Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
1/2상
완료
NCT02719574
| 대상 질환 | Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | Forma Therapeutics, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 336 명 |
|---|
| 중재(약물) | FT-2102 (olutasidenib), Azacitidine, Cytarabine |
|---|
| 시작일 | 2016년 4월 30일 |
|---|
| 완료일 | 2023년 12월 28일 |
|---|
| 결과 공개일 | 2025년 6월 26일 |
|---|
요약
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of FT-2102 (olutasidenib) (single agent) and FT-2102 (olutasidenib) + azacitidine (combination agent) administered via one or more intermittent dosing schedules followed by a dose expansion part. The dose expansion part will enroll patients in up to 5 expansion cohorts, exploring single-agent FT-2102 (olutasidenib) activity as well as combination activity with azacitidine or cytarabine. Following the completion of the relevant Phase 1 cohorts, Phase 2 will begin enrollment. Patients will be enrolled across 8 different cohorts, examining the effect of FT-2102 (olutasidenib) (as a single agent) and FT-2102 (olutasidenib) + azacitidine (combination) on various AML/MDS disease states.
Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Phase 1: From start of drug administration (Day 1) up to 28 days after last dose of study drug (up to 82 months) · Participants
| Phase 1: FT-2102 (Single Agent) | 16 Participants |
|---|
| Phase 1: Total FT-2102 (Single Agent) | 31 Participants |
|---|
| Phase 1: FT-2102 + Azacitidine (Combination Therapy) | 39 Participants |
|---|
| Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) | 46 Participants |
|---|
| Phase 1: FT-2102 (Single Agent) | 10 Participants |
|---|
| Phase 1: Total FT-2102 (Single Agent) | 23 Participants |
|---|
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Laboratory Values
Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months) · Participants
| Phase 1: FT-2102 (Single Agent) | 15 Participants |
|---|
| Phase 1: Total FT-2102 (Single Agent) | 30 Participants |
|---|
| Phase 1: FT-2102 + Azacitidine (Combination Therapy) | 38 Participants |
|---|
| Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) | 45 Participants |
|---|
| Phase 1: FT-2102 (Single Agent) | 0 Participants |
|---|
| Phase 1: Total FT-2102 (Single Agent) | 0 Participants |
|---|
Phase 1: Number of Participants With Change From Baseline in Clinically Significant Abnormal Electrocardiogram (ECG)
Phase 1: From Baseline up to 28 days after last dose of study drug (up to 82 months) · Participants
| Phase 1: FT-2102 (Single Agent) | 10 Participants |
|---|
| Phase 1: Total FT-2102 (Single Agent) | 16 Participants |
|---|
| Phase 1: FT-2102 + Azacitidine (Combination Therapy) | 23 Participants |
|---|
| Phase 1: Total FT-2102; FT-2102 + Azacitidine (Combination Therapy) | 26 Participants |
|---|
| Phase 1: FT-2102 (Single Agent) | 4 Participants |
|---|
| Phase 1: Total FT-2102 (Single Agent) | 11 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.